Sunday, June 14, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 248 of 1,261

  1. US 11400143

    Compositions and methods for treatment of homocystinuria

    The Regents of the University of Colorado · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  2. US 11400150

    Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  3. US 11401246

    Triazole glycolate oxidase inhibitors

    Century Therapeutics, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  4. US 11400116

    Systems and methods for targeting cancer cells

    The Regents of the University of California · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  5. US 11400118

    Methods for production of platelets from pluripotent stem cells and compositions thereof

    Astellas Institute for Regenerative Medicine · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  6. US 11400096

    Small molecules for the treatment of autoimmune disorders

    The Board of Regents of the University of Texas System · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  7. US 11400123

    Combination product for prophylaxis and treatment of irritable bowel syndrome

    PrecisionBiotics Group Limited · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  8. US 11401286

    Heteroaryl inhibitors of PDE4

    Tetra Discovery Partners · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  9. US 11401322

    Immunoglobulin chimeric monomer-dimer hybrids

    BIOVERATIV THERAPEUTICS INC. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  10. US 11401328

    Antibodies binding to ILT4

    Five Prime Therapeutics, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  11. US 11400105

    Anti-inflammatory properties of marine lipid compositions

    AKER BIOMARINE ANTARCTIC AS · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  12. US 11401332

    Proteolytically cleavable chimeric polypeptides and methods of use thereof

    The Regents of the University of California · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  13. US 11401503

    Methods of growing tumor infiltrating lymphocytes in gas-permeable containers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  14. US 11400030

    Two-paste dental curable composition

    KURARAY NORITAKE DENTAL INC. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  15. US 11401532

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  16. US 11401513

    Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use

    Catalyst Biosciences, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  17. US 11401510

    Generation of airway basal stem cells from human pluripotent stem cells

    The Board of Regents of the University of Texas System · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  18. US 11401507

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Iovance Biotherapeutics, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  19. US 11401506

    Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

    Board nf Regents The Inivercitvof Texas Cvctom · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  20. US 11401517

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  21. US 11401512

    Engineered target specific nucleases

    Sangamo Therapeutics, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  22. US 11401387

    Photocontrolled dynamic covalent linkers for polymer networks

    Northwestern University · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  23. US 11401341

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  24. US 11401346

    Nucleic acids encoding plasma kallikrein binding proteins

    Takeda Pharmaceutical Company Limited · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.